Anaheim, CA - Ranolazine, a partial inhibitor of fatty-acid oxidation, may represent the first new class of antianginal drug in over 20 years, according to Dr Bernard Chaitman (St Louis University, St ...

Despite appropriate use criteria advocating the importance of trying 2 or more antianginal drugs prior to invasive treatment of coronary artery disease (CAD), up to one-third of patients undergoing ...

The researchers conducted and extensive literature search (1945-2014) for randomized, controlled trials that compared anti-anginal drug efficacy for managing stable angina. WASHINGTON, DC—While ...

For patients undergoing elective percutaneous coronary intervention (PCI), pretreatment with the antianginal agent ranolazine substantially reduces the risk of periprocedural myocardial infarction (MI ...

After successful percutaneous coronary intervention (PCI), prophylactic use of trimetazidine on top of optimal medical therapy offered no additional relief from chest pain nor reduction in cardiac ...

London, UK - The Impact Of Nicorandil in Angina (IONA) study, showing a reduction in cardiovascular (CV) events in patients with stable angina with nicorandil, has been published in the April 13, 2002 ...

(HealthDay News) — Newer antianginal drugs (AA medications) such as ranolazine show substantial outcome improvements in chronic stable angina pectoris (CSA) compared to traditional medications, ...

Despite the availability of a number of antianginal agents, many patients with stable coronary artery disease (CAD) have persistent angina. Even following CABG surgery or percutaneous coronary ...

HealthDay News — Newer antianginal drugs (AA medications) such as ranolazine show substantial outcome improvements in chronic stable angina pectoris (CSA) compared to traditional medications, ...